eRF3a/GSPT1 12-GGC allele increases the susceptibility for breast cancer development

Oncology Reports

Volumn 21, Issue 6, 2009, Pages 1551-1558

  Malta Vacas, Joana ^a   Chauvin, Celine ^d   Gonçalves, Lucilia ^b   Nazaré, Antonia ^b   Carvalho, Carlos ^b   Monteiro, Carolino ^c   Bagrel, Denyse ^e   Jean Jean, Olivier ^f   Brito, Miguel ^a  

^a INSTITUTO POLITÉCNICO DE LISBOA   (Portugal)

^b HOSPITAL FERNANDO FONSECA   (Portugal)

^c RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^d INSERM   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

Breast cancer; eRF3a GSPT1 gene; STR polymorphism; Susceptibility allele marker; Translation release factor

Indexed keywords

CYTOSINE; EUKARYOTIC RELEASE FACTOR 3A; GUANINE; MESSENGER RNA; TRANSLATION TERMINATION FACTOR; UNCLASSIFIED DRUG; PEPTIDE CHAIN RELEASE FACTOR 3; PEPTIDE-CHAIN-RELEASE FACTOR 3;

ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC CODE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRANSLATION REGULATION; BREAST TUMOR; CASE CONTROL STUDY; CELL LINE; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PROGNOSIS; RISK; RISK ASSESSMENT; RISK FACTOR; RNA INTERFERENCE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; PEPTIDE TERMINATION FACTORS; POLYMORPHISM, GENETIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; RNA INTERFERENCE; TRANSFECTION;

EID: 67649990852     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000387     Document Type: Article

References (29)

1. Clemens MJ and Bommer UA: Translational control: the cancer connection. Int J Biochem Cell Biol 31: 1-23, 1999.
2. Ruggero D and Pandolfi PP: Does the ribosome translate cancer? Nat Rev Cancer 3: 179-192, 2003.
3. Rajasekhar VK and Holland EC: Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene 23: 3248-3264, 2204.
4. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW and Sonenberg N: eIF4E - from translation to transformation. Oncogene 23: 3172-3179, 2004.
5. Anand N, Murthy S, Amann G, et al: Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 31: 301-305, 2002.
6. Malta-Vacas J, Aires C, Costa P, et al: Differential expression of the eukaryotic release factor 3 (ERF3/GSPT1) according to gastric cancer histological types. J Clin Pathol 58: 621-625, 2005.
7. Zhouravleva G, Frolova L, Le Goff X, et al: Termination of translation in eukaryotes in governed by two interacting polypeptide chain release factors, ERF1 and ERF3. EMBO J 14: 4065-4072, 1995.
8. Hoshino S, Miyazawa H, Enomoto T, et al: A human homologue of the yeast GST1 gene codes for a GTP-binding protein and is expressed in a proliferation-dependent manner in mammalian cells. EMBO J 8: 3807-3814, 1989.
9. Kodama H, Ito K and Nakamura Y: The role of N-terminal domain of translational release factor ERF3 for the control of functionality and stability in S. cerevisiae. Genes Cells 12: 639-650, 2007.
10. Volkov K, Osipov K, Valouev I, Inge-Vechtomov S and Mironova L: N-terminal extension of Saccharomyces cerevisiae translation termination factor ERF3 influences the suppression efficiency of sup35 mutations. FEMS Yeast Res 7: 357-365, 2007.
11. Ozawa K, Murakami Y, Eki T, et al: Mapping of the human GSPT1 gene, a human homolog of the yeast GST1 gene, to chromosomal band 16p13.1. Somat Cell Mol Genet 18: 189-194, 1992.
12. Hansen LL, Jakobsen CG and Justesen J: Assignment of the human peptide chain release factor 3 (GSPT2) to Xp11.23 - >p11.21 and of the distal marker DXS1039 by radiation hybrid mapping. Cytogenet Cell Genet 86: 250-251, 1999.
13. Hoshino S, Imai M, Mizutani M, et al: Molecular cloning of a novel member of the eukaryotic polypeptide releasing factors (eRF). Its identification as eRF3 interacting with eRF1. J Biol Chem 273: 22254-22259, 1998.
14. Tallheden T, Karlsson C, Brunner A, et al: Gene expression during redifferentiation of human articular chondrocytes. Osteoarthritis Cartilage 12: 525-535, 2004.
15. Brito M, Malta-Vacas J, Carmona B, et al: Polyglycine expansions in eRF3/GSPT1 are associated with gastric cancer susceptibility. Carcinogenesis 26: 2046-2049, 2005.
16. Easton D, Pooley KA, Dunning AM, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1095, 2007.
17. Coombs N, Gough A and Primrose N: Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. Nucleic Acids Res 27: e12, 1999.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
19. Chauvin C, Salhi S, Le Goff C, Viranaicken W, Diop D and Jean-Jean O: Involvement of human release factors eRF3a and eRF3b in translation termination and regulation of the termination complex formation. Mol Cell Biol 25: 5801-5811, 2005.
20. Raymond M and Rousset F: GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Heredity 86: 248-249, 1995.
21. Sokal RR and Rohlf JF: Biometry, the Principle and Practice of Statistics in Biological Research. 3rd edition. W.H. Freeman and Company, New York, 1995.
22. Hinestrosa MC, Dickersin K, Klein P, et al: Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer 7: 309-315, 2007.
23. Uchida N, Hoshino S, Imataka H, Sonenberg N and Katada T: A novel role of the mammalian GSPT/eRF3 associating with Poly(A)-binding protein in cap/poly(A)-dependent translation. J Biol Chem 277: 50286-50292, 2002.
24. Hosoda N, Kobayashi T, Uchida N, et al: Translation termination factor eRF3 mediates mRNA decay through the regulation of deadenylation. J Biol Chem 278: 38287-38291, 2003.
25. Hegde R, Srinivasula SM, Datta P, et al: The polypeptide chain releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein. J Biol Chem 278: 38699-38706, 2003.
26. Holland EC, Sonenberg N, Pandolfi PP and Thomas G: Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23: 3138-3144, 2004.
27. Dua K, Williams TM and Beretta L: Translational control of the proteome: relevance to cancer. Proteomics 1: 1191-1199, 2001.
28. Chauvin C, Salhi S and Jean-Jean O: Human eukaryotic release factor 3a depletion causes cell cycle arrest at G1 phase through inhibition of the mTOR pathway. Mol Cell Biol 27: 5619-5629, 2007.
29. Corradetti MN and Guan KL: Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 25: 6347-6360, 2006.